Latest news about Sudeep Pharma
Sudeep Pharma
1,131.15
+19.35(+1.74%)
Company Performance:
View Company Insights1D+1.74%
1M+30.02%
6M+79.09%
1Y+46.12%
5Y+46.12%
More news about Sudeep Pharma
11Jul 26
Sudeep Pharma AGM scheduled for Aug 4, 2026
Sudeep Pharma Limited has scheduled its 37th Annual General Meeting for August 4, 2026, via video conferencing. Shareholders will vote on a final dividend of ₹1.50 per share for FY 2025-26 and the ratification of the Employee Stock Option Scheme 2025. The record date for dividend eligibility is July 23, 2026.
27Jun 26
Sudeep Pharma appoints Milin Mehta as Non-Executive Non-Independent Director
Sudeep Pharma Ltd announced the appointment of Mr. Milin Mehta as an Additional Director in the Non-Executive Non-Independent category effective June 26, 2026, pending shareholder approval. The Board approved the appointment, confirming Mr. Mehta is not debarred from holding the directorship. Mr. Mehta, a Chartered Accountant and Managing Partner at K C Mehta & Co LLP, brings over three decades of experience in tax and regulatory practices.
29May 26
Sudeep Pharma FY26 revenue rises 27.9% to ₹642.3 crore
Sudeep Pharma reported a 27.9% YoY rise in FY26 revenue to ₹642.3 crore, with PAT increasing to ₹174.3 crore. The specialty ingredients vertical grew 62% to ₹280 crore, while the battery materials project is on track for April 2027 commissioning.
23May 26
Sudeep Pharma FY26 Consolidated Net Profit Rises 26%; Dividend Declared
Sudeep Pharma Limited reported audited consolidated FY26 total income from operations of ₹67,084.34 lakhs and net profit after tax of ₹17,428.47 lakhs, up ~26% year-on-year, with annual EPS of ₹15.50. Q4 FY26 consolidated net profit stood at ₹4,853.82 lakhs on revenues of ₹18,876.34 lakhs. The board recommended a final dividend of ₹1.50 per share and outlined capacity expansion plans across Pharma, Specialty Ingredients, and Battery Materials segments for FY27.
23May 26
Sudeep Pharma to attend investor meets on May 28, June 8
Sudeep Pharma Limited announced its participation in two investor conferences in Mumbai on May 28 and June 8, 2026. Officials will meet analysts and institutional investors during the 360 ONE Capital and ICICI Securities events. The company confirmed that only public information will be discussed.
10Apr 26
Sudeep Pharma Limited Submits Q4FY26 Compliance Certificate Under SEBI Depositories Regulations
Sudeep Pharma Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 10, 2026, covering the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirmed no demat requests were processed as all company shares remain in electronic mode. Company Secretary Dimple Mehta submitted the documentation to NSE and BSE, ensuring continued regulatory compliance for the Gujarat-based pharmaceutical company.
17Mar 26
Sudeep Pharma Limited Schedules Analyst and Investor Meetings for March 23, 2026
Sudeep Pharma Limited has scheduled analyst and institutional investor meetings for March 23, 2026 in Mumbai, starting from 12:00 pm onwards. The company filed this regulatory disclosure on March 17, 2026, under SEBI listing regulations, confirming that discussions will be limited to publicly available information with no unpublished price sensitive information to be shared. The meetings will be conducted in both one-on-one and group formats as part of the pharmaceutical company's investor relations activities.
12Feb 26
Sudeep Pharma Submits Q3FY26 Earnings Call Transcript Following Strong Results
Sudeep Pharma Limited submitted its Q3FY26 earnings call transcript to stock exchanges, detailing strong financial performance with 52% revenue growth and strategic initiatives including battery materials expansion. The earnings call provided comprehensive insights into the company's diversified growth across pharmaceutical, specialty ingredients, and emerging battery materials segments.
10Feb 26
Sudeep Pharma Makes Q3FY26 Earnings Call Audio Recording Available Online
Sudeep Pharma Limited has successfully uploaded the audio recording of its Q3FY26 earnings call held on February 9, 2026, making it accessible to stakeholders through its official website. The company has maintained full regulatory compliance by informing NSE and BSE about the availability and will submit a detailed transcript separately.
05Feb 26
Sudeep Pharma Files Regulatory Notice for VP John Garcia's Resignation
Sudeep Pharma Limited has filed mandatory regulatory disclosures with NSE and BSE regarding the resignation of John Garcia, Vice President of Sales & Supply Chain at wholly owned subsidiary Sudeep Pharma USA Inc. Garcia submitted his resignation on February 4, 2026, with an effective date of February 6, 2026, citing pursuit of new challenges and opportunities as the reason for departure.
22Jan 26
Sudeep Pharma Subsidiary Acquires Gujarat Land Rights for ₹20.97 Crores Manufacturing Facility
Sudeep Pharma Limited's wholly owned subsidiary, Sudeep Advanced Materials Private Limited, has acquired leasehold rights to 80,980.19 square meters of land in Dahej, Gujarat for ₹20.97 crores. The land, purchased from DCM Shriram Fine Chemicals Limited, will be used to establish a commercial manufacturing facility for battery-grade iron phosphate. The transaction is subject to regulatory approvals and represents the company's strategic expansion into battery materials manufacturing.
16Jan 26
Sudeep Pharma Limited Updates CIN and Company Status Following Stock Exchange Listing
Sudeep Pharma Limited has successfully updated its Corporate Identification Number (CIN) from U24231GJ1989PLC013141 to L24231GJ1989PLC013141 on the MCA website following its listing on BSE and NSE on November 28, 2025. The company's status has been changed from unlisted to listed, with the updated master data showing authorized capital of ₹15.00 crores and paid-up capital of ₹11.29 crores. The pharmaceutical company, incorporated in 1989 and based in Gujarat, maintains active compliance status under ROC Ahmedabad jurisdiction.
22Dec 25
Sudeep Pharma Submits Q2FY26 Earnings Call Audio Recording to Stock Exchanges
Sudeep Pharma Limited has completed its Q2FY26 earnings call and submitted the audio recording to stock exchanges in compliance with SEBI regulations. The call was held on December 22, 2025, to discuss performance for the quarter and half-year ended September 30, 2025, with the recording now available on the company's website for stakeholder access.
22Dec 25
Sudeep Pharma Q2 Results: EBITDA Drops 12.6% to ₹55.5 Cr, Margin Shrinks
Sudeep Pharma Limited reported Q2 financial results showing revenue growth of 6.7% to ₹162.80 crores, but faced significant profitability pressures with EBITDA declining 12.6% to ₹55.50 crores and EBITDA margin compressing to 34.09% from 42.66% year-on-year. Net profit also decreased 6.2% to ₹45.70 crores, indicating operational challenges despite top-line growth.
20Dec 25
Sudeep Pharma Completes Q2FY26 Results Publication in Newspapers
Sudeep Pharma Limited completed regulatory compliance by publishing its Q2FY26 financial results extract in newspapers on December 20, 2025. The company reported consolidated revenue of ₹16,266.62 crores and net profit of ₹4,677.82 crores, with detailed results available on stock exchanges and company website.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Laurus Labs
Aurobindo Pharma
1,910.00
(+0.40%)
8,496.00
(-1.17%)
4,886.50
(-0.20%)
1,437.90
(+0.40%)
1,103.80
(-1.45%)
2,188.00
(-0.63%)
1,190.00
(+1.30%)
2,374.50
(-0.40%)
1,801.00
(-0.06%)
1,608.00
(-0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
